Ho Sung Cho
Directeur/Membre du Conseil chez BIOCOM
Profil
Ho Sung Cho is currently the Director at BIOCOM and the Director at California Biomedical Innovation Alliance.
Previously, he worked as the Associate Director-Protein Chemistry at Xencor, Inc., Director at Viron Therapeutics, Inc., Director at Boundless Bio, Inc., Vice President-Biotherapeutics at Celgene Corp., Team Leader at Exelixis, Inc., Vice President-Technology & Process Development at Ambrx, Inc., Staff Scientist at Lawrence Berkeley National Laboratory, and Medicinal Chemist at Burroughs Wellcome.
He holds a doctorate degree from the University of California.
Postes actifs de Ho Sung Cho
| Sociétés | Poste | Début |
|---|---|---|
BIOCOM
 BIOCOM Miscellaneous Commercial ServicesCommercial Services BIOCOM provides scientific and technological services. The firm focuses that positively influence the growth of the life science industry, including capital formation, public policy, workforce development and scientific discovery and development. The company was founded in 1995 and is headquartered in San Diego, CA. | Directeur/Membre du Conseil | 27/02/2017 |
California Biomedical Innovation Alliance
 California Biomedical Innovation Alliance BiotechnologyHealth Technology California Biomedical Innovation Alliance provides biomedical advocacy and community services. The private company is based in South San Francisco, CA and has subsidiaries in United States. The CEO of the company is Sara Radcliffe. | Directeur/Membre du Conseil | 28/08/2017 |
Anciens postes connus de Ho Sung Cho
| Sociétés | Poste | Fin |
|---|---|---|
| CELGENE | Corporate Officer/Principal | 01/11/2019 |
| BOUNDLESS BIO, INC. | Directeur/Membre du Conseil | - |
Viron Therapeutics, Inc.
 Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Directeur/Membre du Conseil | - |
| Burroughs Wellcome | Corporate Officer/Principal | - |
Lawrence Berkeley National Laboratory
 Lawrence Berkeley National Laboratory Miscellaneous Commercial ServicesCommercial Services Lawrence Berkeley National Laboratory engages on research of environmental studies, nanoscience, and quantitative biology, physics and nuclear energy. The lab is funded by the U.S. Department of Energy and managed by the University of California. It was founded in 1931 by Ernest Orlando Lawrence and is headquartered in Berkeley, CA. | Corporate Officer/Principal | - |
Formation de Ho Sung Cho
| University of California | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| XENCOR, INC. | Health Technology |
| EXELIXIS, INC. | Health Technology |
| BOUNDLESS BIO, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Ambrx, Inc.
 Ambrx, Inc. Pharmaceuticals: MajorHealth Technology Ambrx, Inc. engages in discovering and developing of protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio-therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA. | Health Technology |
Lawrence Berkeley National Laboratory
Lawrence Berkeley National Laboratory Miscellaneous Commercial ServicesCommercial Services Lawrence Berkeley National Laboratory engages on research of environmental studies, nanoscience, and quantitative biology, physics and nuclear energy. The lab is funded by the U.S. Department of Energy and managed by the University of California. It was founded in 1931 by Ernest Orlando Lawrence and is headquartered in Berkeley, CA. | Commercial Services |
| Burroughs Wellcome | |
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Health Technology |
BIOCOM
BIOCOM Miscellaneous Commercial ServicesCommercial Services BIOCOM provides scientific and technological services. The firm focuses that positively influence the growth of the life science industry, including capital formation, public policy, workforce development and scientific discovery and development. The company was founded in 1995 and is headquartered in San Diego, CA. | Commercial Services |
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
California Biomedical Innovation Alliance
California Biomedical Innovation Alliance BiotechnologyHealth Technology California Biomedical Innovation Alliance provides biomedical advocacy and community services. The private company is based in South San Francisco, CA and has subsidiaries in United States. The CEO of the company is Sara Radcliffe. | Health Technology |
